Taipei, February 15, 2016 – Polaris Group announced today that its shares have been listed for trading on the Emerging Stock Board (ESB) of the Taipei Exchange (TPEx).
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x96-350x96.png00Emmyhttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x96-350x96.pngEmmy2016-02-15 18:06:262018-02-19 18:08:26Polaris Group Shares Listed on the Emerging Stock Board of the Taipei Exchange
SAN DIEGO, January 22, 2016 – Polaris Group announced today that its wholly owned subsidiary DesigneRx Pharmeceuticals (DRX) (Chengdu) has completed the building constructions of its GMP manufacturing facility for biological drugs in Chengdu, China.
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x96-350x96.png00Emmyhttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x96-350x96.pngEmmy2016-01-22 18:09:162018-02-19 18:11:00Polaris Group Completes Construction of Its GMP Manufacturing Facility in China
VACAVILLE, CALIFORNIA, January 5, 2016 – Polaris Group today announced that its subsidiary DesigneRx Pharmaceuticals, Inc. (DRX) has completed construction of its new, expanded cGMP facility for manufacturing biological pharmaceuticals in Vacaville, California.
Taipei, October 12, 2015 – Polaris Group announced today that it has acquired ownership of all outstanding shares of TDW Group in a share exchange transaction. Prior to the acquisition, Polaris Group owned a 27% stake in TDW Group and following the acquisition, TDW Group became a wholly-owned subsidiary of Polaris Group.
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x96-350x96.png00Emmyhttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x96-350x96.pngEmmy2015-10-12 18:15:342018-02-19 18:17:04Polaris Group Acquires 100% Ownership of TDW Group
SAN DIEGO, June 25, 2015 – Polaris Group announced today that its lead therapeutic ADI‑PEG 20 (pegylated arginine deiminase) was shown to have activity against primary acute myeloid leukemia (AML), both in vitro and in vivo, as reported in a research article published in the journal Blood.
SAN DIEGO, May 22, 2015 – Polaris Group announced today that it has filed a protocol amendment with the FDA to include two additional dose expansion cohorts treating uveal melanoma and glioblastoma in its ongoing phase 1 study that tests its lead therapeutic ADI‑PEG 20 (pegylated arginine deiminase) in combination treatment with the standard first-line chemotherapy (cisplatin + pemetrexed doublet) in malignant plural mesothelioma (MPM) and non-squamous non-small cell lung carcinoma (NSCLC).
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x96-350x96.png00Emmyhttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x96-350x96.pngEmmy2015-05-22 18:19:142018-02-19 18:20:20Additional Tumor Type Cohorts Added to the Ongoing Phase 1 Study Combining ADI‑PEG 20 with Cisplatin and Pemetrexed Based on New Research Results
SAN DIEGO, April 22, 2015 – Polaris Group announced today that its lead therapeutic ADI‑PEG 20 (pegylated arginine deiminase) restored cisplatin sensitivity to multiple cisplatin-resistant (CR) non-small cell lung carcinoma (NSCLC) cell lines in vitro.
SAN DIEGO, February 3, 2015 – Polaris Group announced today that the first patient has been dosed in its Phase 1 trial of ADI‑PEG 20 in combination with folinic acid (leucovorin), fluorouracil and oxaliplatin (FOLFOX) for the treatment of advanced gastrointestinal malignancies.
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x96-350x96.png00Emmyhttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x96-350x96.pngEmmy2015-02-03 18:22:102018-02-19 18:24:49Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI‑PEG 20 plus FOLFOX in Advanced Gastrointestinal Malignancies
SAN DIEGO, December 18, 2014 – Polaris Group announced today that its lead product candidate ADI‑PEG 20 (pegylated arginine deiminase) has received orphan drug designation for the treatment of malignant pleural mesothelioma (MPM) in the United States and in the European Union. Orphan drug designation grants special status to a drug or biological product to treat a rare disease or condition.
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x96-350x96.png00Emmyhttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x96-350x96.pngEmmy2014-12-18 18:24:532018-02-19 18:26:40Polaris Group Lead Therapeutic Candidate ADI‑PEG 20 Receives Orphan Drug Designation in the United States and the European Union for the Treatment of Malignant Pleural Mesothelioma
SAN DIEGO, December 10, 2014 – Polaris Group announced today that the first patient has been dosed in its Phase 1 trial of ADI‑PEG 20 in combination with sorafenib, a current first line therapy, for the treatment of advanced hepatocellular carcinoma (HCC).
http://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x96-350x96.png00Emmyhttp://polarispharma.com/wp-content/uploads/Polaris_Logo_FullColor_Old-350x96-350x96.pngEmmy2014-12-10 18:26:592018-02-19 18:28:07Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI‑PEG 20 Plus Sorafenib in Advanced Hepatocellular Carcinoma
Polaris Group Shares Listed on the Emerging Stock Board of the Taipei Exchange
NewsTaipei, February 15, 2016 – Polaris Group announced today that its shares have been listed for trading on the Emerging Stock Board (ESB) of the Taipei Exchange (TPEx).
Polaris Group Completes Construction of Its GMP Manufacturing Facility in China
NewsSAN DIEGO, January 22, 2016 – Polaris Group announced today that its wholly owned subsidiary DesigneRx Pharmeceuticals (DRX) (Chengdu) has completed the building constructions of its GMP manufacturing facility for biological drugs in Chengdu, China.
Polaris Group Subsidiary Announces Expansion of cGMP Manufacturing Facility
NewsVACAVILLE, CALIFORNIA, January 5, 2016 – Polaris Group today announced that its subsidiary DesigneRx Pharmaceuticals, Inc. (DRX) has completed construction of its new, expanded cGMP facility for manufacturing biological pharmaceuticals in Vacaville, California.
Polaris Group Acquires 100% Ownership of TDW Group
NewsTaipei, October 12, 2015 – Polaris Group announced today that it has acquired ownership of all outstanding shares of TDW Group in a share exchange transaction. Prior to the acquisition, Polaris Group owned a 27% stake in TDW Group and following the acquisition, TDW Group became a wholly-owned subsidiary of Polaris Group.
Polaris Group’s Lead Therapeutic ADI‑PEG 20 Shows Activity against Primary Acute Myeloid Leukemia
NewsSAN DIEGO, June 25, 2015 – Polaris Group announced today that its lead therapeutic ADI‑PEG 20 (pegylated arginine deiminase) was shown to have activity against primary acute myeloid leukemia (AML), both in vitro and in vivo, as reported in a research article published in the journal Blood.
Additional Tumor Type Cohorts Added to the Ongoing Phase 1 Study Combining ADI‑PEG 20 with Cisplatin and Pemetrexed Based on New Research Results
NewsSAN DIEGO, May 22, 2015 – Polaris Group announced today that it has filed a protocol amendment with the FDA to include two additional dose expansion cohorts treating uveal melanoma and glioblastoma in its ongoing phase 1 study that tests its lead therapeutic ADI‑PEG 20 (pegylated arginine deiminase) in combination treatment with the standard first-line chemotherapy (cisplatin + pemetrexed doublet) in malignant plural mesothelioma (MPM) and non-squamous non-small cell lung carcinoma (NSCLC).
Polaris Group’s ADI‑PEG 20 Restores Cisplatin Sensitivity to Cisplatin-Resistant Non-Small Cell Lung Carcinoma Cells
NewsSAN DIEGO, April 22, 2015 – Polaris Group announced today that its lead therapeutic ADI‑PEG 20 (pegylated arginine deiminase) restored cisplatin sensitivity to multiple cisplatin-resistant (CR) non-small cell lung carcinoma (NSCLC) cell lines in vitro.
Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI‑PEG 20 plus FOLFOX in Advanced Gastrointestinal Malignancies
NewsSAN DIEGO, February 3, 2015 – Polaris Group announced today that the first patient has been dosed in its Phase 1 trial of ADI‑PEG 20 in combination with folinic acid (leucovorin), fluorouracil and oxaliplatin (FOLFOX) for the treatment of advanced gastrointestinal malignancies.
Polaris Group Lead Therapeutic Candidate ADI‑PEG 20 Receives Orphan Drug Designation in the United States and the European Union for the Treatment of Malignant Pleural Mesothelioma
NewsSAN DIEGO, December 18, 2014 – Polaris Group announced today that its lead product candidate ADI‑PEG 20 (pegylated arginine deiminase) has received orphan drug designation for the treatment of malignant pleural mesothelioma (MPM) in the United States and in the European Union. Orphan drug designation grants special status to a drug or biological product to treat a rare disease or condition.
Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI‑PEG 20 Plus Sorafenib in Advanced Hepatocellular Carcinoma
NewsSAN DIEGO, December 10, 2014 – Polaris Group announced today that the first patient has been dosed in its Phase 1 trial of ADI‑PEG 20 in combination with sorafenib, a current first line therapy, for the treatment of advanced hepatocellular carcinoma (HCC).